Compare AstraZeneca plc (AZN) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Yum! Brands, Inc. — how do they compare? AstraZeneca plc trades at $166.72 (market cap $253.13B), while Yum! Brands, Inc. trades at $158.18 (market cap $43.60B). The key difference: AstraZeneca plc is far larger — about 5.8× Yum! Brands, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | YUM | |
|---|---|---|
Market Cap | $253.13B | $43.60B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $168.16 |
52-Week Low | $137.44 | $138.21 |
Enterprise Value | $279.37B | $54.86B |
Dividend Yield | 1.92% | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
YUM Brands trades at $161.69, down 1.13% today, with a bullish technical signal from moving averages and key resistance at $163. The company reported Q1 2026 EPS of $1.50, beating expectations, while revenue grew to $8.21B in 2025. Recent news includes a Taco Bell health investigation and the $2.7B Pizza Hut sale, which may streamline operations.
YUM's outlook is supported by strong cash flow and margin stability, but high debt and competitive pressures pose risks. Analysts maintain a $174.60 price target with a mixed buy/hold consensus. The stock offers growth potential post-Pizza Hut divestiture, though investor sentiment is cautious amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
